Latest Media Releases

All A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Phylogica, R&D Tax Incentive of $1.9M for Phylomer Development Support (ASX:PYC)

PERTH, AUSTRALIA: 13 September 2012 – Leading Australian peptide drug discovery company Phylogica Ltd (ASX:PYC, XETRA: PH7) expects to receive a cash payment of approximately $1.9 million thi...read more

Phylogica Licenses to Le Métier de Beauté Skin-Repair Peptide for Cosmetic Market (ASX:PYC)

PERTH, AUSTRALIA: September 12, 2012 – Phylogica Ltd (ASX:PYC, XETRA: PH7), a leading Australian peptide drug discovery company, has licensed its skin-repair Phylomer peptide PYC35 to Le M&ea...read more

Phylogica Ltd, Annual Report 2012 (ASX:PYC)

Chairman's Report This has been an important year for Phylogica, a period in which our Phylomer technology gained further global recognition as a powerful platform for the discovery of nov...read more

Phylogica, Shareholder Newsletter (ASX:PYC)

In this edition: Partnership activities have never been busier Pharma industry reorganisations Phylogica is not immune to industry dynamics Biological drugs are leading the way Secur...read more

Phylogica, Research Milestone in Pfizer Collaboration Achieved (ASX:PYC)

PERTH, AUSTRALIA: May 31, 2012 – Phylogica Ltd (ASX:PYC, XETRA:PH7), a public Australian peptide drug discovery company, announced today that it has successfully achieved a research milestone...read more

Phylogica, Patent for Synthetic Phylomer Libraries Granted (ASX:PYC)

PERTH, AUSTRALIA: April 26, 2012 – Phylogica Ltd (ASX:PYC, XETRA: PH7), a leading Australian peptide drug discovery company, announced today that it has been granted a new patent (AU: 2007218...read more

Phylogica, US Patent is Granted on Neuroprotective Phylomer Peptide (ASX:PYC)

PERTH, AUSTRALIA: February 23, 2012 – Phylogica Ltd (ASX:PYC, XETRA:PH7), a leading Australian peptide drug discovery company, announced today that it has been granted a new US Patent (Patent...read more

SHAREHOLDER UPDATE (ASX:PYC)

Phylogica Ltd (ASX: PYC, XETRA: PH7) has signed its fourth partnership with a major pharmaceutical company. Today, we have announced a Collaboration and Option agreement with Janssen Biotech, Inc.,...read more

PHYLOGICA AND PFIZER COMPLETE FIRST STAGE OF PEPTIDE VACCINE COLLABORATION (ASX:PYC)

PERTH, AUSTRALIA: December 12, 2011 – Phylogica Ltd (ASX: PYC, XETRA: PH7), a public Australian peptide drug discovery company, announced today the successful completion of the first stage of...read more

Harnessing Biodiversity for Peptide Therapies - Annual General Meeting 24 November 2011 (ASX:PYC)

Investment Highlights - Strategy for rapid revenue growth from fee-for-service alliances - Since 2009, signed partnerships with Roche, AstraZeneca & Pfizer - Positioned for cash flo...read more

PHYLOGICA ADVANCES COLLABORATION IN MEDIMMUNE ANTIBIOTIC DISCOVERY PARTNERSHIP (ASX:PYC)

PERTH, AUSTRALIA: November 21, 2011 – Phylogica Ltd (ASX: PYC, XETRA:PH7), a leading Australian peptide drug discovery company, announced today the progression of its collaboration with MedIm...read more

ANNUAL REPORT 2011 (ASX:PYC)

To view Report please download PDF below:

Annual Report 30 June 2011 (ASX:PYC)

The directors present their report on the consolidated group, comprising Phylogica Limited (referred to in these financial statements as “the Group” or “Phylogica”) and its ...read more

PHYLOGICA ANNOUNCES RBS MORGANS RESEARCH REPORT (ASX:PYC)

PERTH, AUSTRALIA: September 02, 2011 – Phylogica Ltd (ASX: PYC, XETRA:PH7), a leading Australian peptide drug discovery company, is pleased to advise that a new research report has been prepa...read more

PHYLOGICA REPORTS PROMISING DATA ON CELL-PENETRATING PHYLOMER PEPTIDES (ASX:PYC)

PERTH, AUSTRALIA: May 25, 2011 – Phylogica Ltd (ASX: PYC, XETRA: PH7), a leading Australian peptide drug discovery company, announced today promising validation of its novel cell- penetrating...read more

Viewing: 91 - 105 of 116 Previous | Next